<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="72635"><DrugName>ivosidenib</DrugName><DrugNamesKey><Name id="43129774">Tibsovo</Name><Name id="43073900">ivosidenib</Name></DrugNamesKey><DrugSynonyms><Name><Value>isocitrate dehydrogenase inhibitors (cancer), Agios/Celgene</Value></Name><Name><Value>IDH inhibitors (cancer), Agios/Celgene</Value></Name><Name><Value>Agios IDH</Value></Name><Name><Value>IDH-1/IDH-2 inhibitors (cancer), Agios/Celgene</Value></Name><Name><Value>AG-120</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>isocitrate dehydrogenase-1 inhibitor (oral, cancer), Agios/Celgene</Value></Name><Name><Value>AGI-14100</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ivosidenib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>Tibsovo</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>CS-3010</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>1448347-49-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1040627">Agios Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="1040627">Agios Pharmaceuticals Inc</Company><Company id="1126254">CStone Pharmaceuticals Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="15331">Celgene Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="72635" type="Drug"><TargetEntity id="797846" type="siDrug"></TargetEntity><TargetEntity id="796746" type="siDrug">AGI-6780</TargetEntity><TargetEntity id="797849" type="siDrug"></TargetEntity><TargetEntity id="797858" type="siDrug"></TargetEntity><TargetEntity id="797847" type="siDrug"></TargetEntity><TargetEntity id="797848" type="siDrug"></TargetEntity><TargetEntity id="797856" type="siDrug"></TargetEntity><TargetEntity id="797861" type="siDrug"></TargetEntity><TargetEntity id="797843" type="siDrug"></TargetEntity><TargetEntity id="797845" type="siDrug"></TargetEntity><TargetEntity id="797853" type="siDrug"></TargetEntity><TargetEntity id="797844" type="siDrug"></TargetEntity><TargetEntity id="797862" type="siDrug"></TargetEntity><TargetEntity id="797863" type="siDrug"></TargetEntity><TargetEntity id="797866" type="siDrug"></TargetEntity><TargetEntity id="797842" type="siDrug"></TargetEntity><TargetEntity id="797854" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="1040627" type="Company"><TargetEntity id="4298032874" type="organizationId">Agios Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1126254" type="Company"><TargetEntity id="5051390424" type="organizationId">CStone Pharmaceuticals Ltd</TargetEntity></SourceEntity><SourceEntity id="15331" type="Company"><TargetEntity id="4295905897" type="organizationId">Celgene Corp</TargetEntity></SourceEntity><SourceEntity id="1108" type="ciIndication"><TargetEntity id="10018338" type="MEDDRA"></TargetEntity><TargetEntity id="D005910" type="MeSH"></TargetEntity><TargetEntity id="-1503483999" type="omicsDisease"></TargetEntity><TargetEntity id="680" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1272" type="ciIndication"><TargetEntity id="D46" type="ICD10"></TargetEntity><TargetEntity id="10028533" type="MEDDRA"></TargetEntity><TargetEntity id="D011289" type="MeSH"></TargetEntity><TargetEntity id="-376765165" type="omicsDisease"></TargetEntity><TargetEntity id="711" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"></TargetEntity><TargetEntity id="519" type="ORPHANET"></TargetEntity><TargetEntity id="-1550871001" type="omicsDisease"></TargetEntity><TargetEntity id="686" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1765" type="ciIndication"><TargetEntity id="D018281" type="MeSH"></TargetEntity><TargetEntity id="70567" type="ORPHANET"></TargetEntity><TargetEntity id="-2122101383" type="omicsDisease"></TargetEntity><TargetEntity id="1844" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2444" type="ciIndication"><TargetEntity id="10008734" type="MEDDRA"></TargetEntity><TargetEntity id="D002813" type="MeSH"></TargetEntity><TargetEntity id="55880" type="ORPHANET"></TargetEntity><TargetEntity id="-158699444" type="omicsDisease"></TargetEntity><TargetEntity id="1357" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="6833" type="ciIndication"><TargetEntity id="10009018" type="MEDDRA"></TargetEntity><TargetEntity id="D015477" type="MeSH"></TargetEntity><TargetEntity id="98823" type="ORPHANET"></TargetEntity><TargetEntity id="-1293987798" type="omicsDisease"></TargetEntity><TargetEntity id="692" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Acute myelogenous leukemia - US - Jul-2018</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1108">Glioma</Indication><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="1731">Acute myelogenous leukemia</Indication><Indication id="1765">Cholangiocarcinoma</Indication><Indication id="2444">Chondrosarcoma</Indication><Indication id="6833">Chronic myelomonocytic leukemia</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="3713">Advanced solid tumor</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="67514">IDH1 gene inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-27T12:04:46.000Z</LastModificationDate><ChangeDateLast>2019-06-24T00:00:00.000Z</ChangeDateLast><AddedDate>2011-07-21T11:53:34.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1040627" linkType="Company"&gt;Agios Pharmaceuticals&lt;/ulink&gt; has developed and launched  ivosidenib (Tibsovo; AG-120; presumed to be AGI-14100), a mutated isocitrate dehydrogenase-1 (IDH1) inhibitor, from a program of isocitrate dehydrogenase (IDH) inhibitors (Agios IDH) [&lt;ulink linkID="1090961" linkType="Reference"&gt;1090961&lt;/ulink&gt;], [&lt;ulink linkID="1626070" linkType="Reference"&gt;1626070&lt;/ulink&gt;]. The product is indicated  in the US for the  oral treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test [&lt;ulink linkID="2056174" linkType="Reference"&gt;2056174&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2018, the  drug was launched in the US for relapsed or refractory AML with a susceptible IDH1 mutation [&lt;ulink linkID="2056485" linkType="Reference"&gt;2056485&lt;/ulink&gt;].  In May 2019, the FDA approved the sNDA  for newly diagnosed AML patients with an IDH1 mutation who are not eligible for standard treatment [&lt;ulink linkID="2147859" linkType="Reference"&gt;2147859&lt;/ulink&gt;]. In December 2018, an MAA was submitted to the EMA for adult patients with IDH1 mutant-positive relapsed or refractory AML [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;]. In February 2019,  an investigator-led, registration-enabling, phase III trial (HOVON150AML) assessing the combination of  ivosidenib or &lt;ulink linkID="86597" linkType="Drug"&gt;enasidenib&lt;/ulink&gt; with standard induction and consolidation chemotherapy was expected to begin later that month in patients with newly diagnosed AML or myelodysplastic syndrome (MDS) with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy  [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;], [&lt;ulink linkID="2127910" linkType="Reference"&gt;2127910&lt;/ulink&gt;].        &lt;/para&gt;&lt;para&gt;Development in other cancer settings is ongoing. In December 2016, a    registration-enabling phase III trial  (ClarIDHy) was initiated in the  US in previously treated patients  with  advanced cholangiocarcinoma [&lt;ulink linkID="1885696" linkType="Reference"&gt;1885696&lt;/ulink&gt;],  [&lt;ulink linkID="1892568" linkType="Reference"&gt;1892568&lt;/ulink&gt;], [&lt;ulink linkID="1903591" linkType="Reference"&gt;1903591&lt;/ulink&gt;];  in February 2019, an sNDA for second line or later IDH1 mutant cholangiocarcinoma was expected to be sumbitted by the end of 2019 [&lt;ulink linkID="2119865" linkType="Reference"&gt;2119865&lt;/ulink&gt;], [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;];  in May 2019, the trial met its primary endpoint  [&lt;ulink linkID="2154688" linkType="Reference"&gt;2154688&lt;/ulink&gt;]. In March 2014, a phase I trial was initiated  in patients  with advanced solid tumors that habor  an IDH 1 mutation, including chondrosarcoma and glioma;    in July 2018, the trial was ongoing [&lt;ulink linkID="1531603" linkType="Reference"&gt;1531603&lt;/ulink&gt;]. At that time, a  phase I study was  initiated  in patients   with advanced hematologic malignancies with an IDH1 mutation; in February 2018,  clinical data were reported for   MDS   patients; at that time, the trial was ongoing [&lt;ulink linkID="1533007" linkType="Reference"&gt;1533007&lt;/ulink&gt;], [&lt;ulink linkID="2005359" linkType="Reference"&gt;2005359&lt;/ulink&gt;]. In January 2019, &lt;ulink linkID="21569" linkType="Company"&gt;Massachusetts General Hospital&lt;/ulink&gt; sponsored phase I trial, to evaluate the drug as a maintenance therapy in patients with  IDH1-mutant myeloid neoplasms following allogeneic stem cell transplantation including patients with  chronic myelomonocytic leukemia was initiated [&lt;ulink linkID="2050118" linkType="Reference"&gt;2050118&lt;/ulink&gt;]. In February 2019, a &lt;ulink linkID="1046900" linkType="Company"&gt;Groupe Francophone des Myelodysplasies&lt;/ulink&gt;-sponsored phase II study for MDS and AML was initiated [&lt;ulink linkID="2137586" linkType="Reference"&gt;2137586&lt;/ulink&gt;].       &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;By December 2016, Agios had several issued and pending US patents covering ivosidenib; in February 2017, the company noted that it owned issued compositions of matter patents protecting the drug [&lt;ulink linkID="1903591" linkType="Reference"&gt;1903591&lt;/ulink&gt;]. &lt;ulink linkID="PA7448332" linkType="Patent"&gt;US-09474779&lt;/ulink&gt; provides patent protection until July 2033.&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Cholangiocarcinoma&lt;/subtitle&gt;In February 2019, subject to positive data from the ClarIDHy study, the company planned to submit an sNDA for second line or later IDH1 mutant cholangiocarcinoma by the end of 2019 [&lt;ulink linkID="2119865" linkType="Reference"&gt;2119865&lt;/ulink&gt;], [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Acute myeloid leukemia&lt;/subtitle&gt;In March 2019, the US FDA granted Breakthrough Therapy designation for ivosidenib in combination with azacitidine for the treatment of newly diagnosed AML with an IDH1 mutation in adult patients who are 75 years of age or older, or who have comorbidities that preclude use of intensive induction chemotherapy [&lt;ulink linkID="2134889" linkType="Reference"&gt;2134889&lt;/ulink&gt;], [&lt;ulink linkID="2138392" linkType="Reference"&gt;2138392&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2018, Agios planned  to submit an sNDA for the treatment of newly diagnosed AML patients with an IDH1 mutation  not eligible for standard treatment  by the end of January 2019 [&lt;ulink linkID="2089652" linkType="Reference"&gt;2089652&lt;/ulink&gt;]. In December 2018, the company submitted the sNDA for newly diagnosed AML patients with an IDH1 mutation who are not eligible for standard treatment [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;]. In February 2019, the FDA accepted the sNDA filing  with Priority Review; the  target PDUFA date was set for June 21, 2019 [&lt;ulink linkID="2121506" linkType="Reference"&gt;2121506&lt;/ulink&gt;]. In May 2019, the US FDA approved the sNDA for the adult patients with newly diagnosed AML with a susceptible IDH1 mutation as detected by an FDA-approved test and  who are ≥ 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. At that time, the sNDA was accepted under the FDA's Real-Time Oncology Review pilot program [&lt;ulink linkID="2147859" linkType="Reference"&gt;2147859&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, an NDA was filed with a request for Priority Review for the treatment of  relapsed or refractory AML with an IDH1 mutation  [&lt;ulink linkID="1993762" linkType="Reference"&gt;1993762&lt;/ulink&gt;]; in February 2018, the FDA accepted the NDA for Priority Review with a PDUFA date of August 21, 2018 [&lt;ulink linkID="2005726" linkType="Reference"&gt;2005726&lt;/ulink&gt;]. In July 2018, the FDA approved the drug for the oral treatment of adult patients with relapsed or refractory AML with a susceptible IDH1 mutation, based on the clinical data from Study AG120-C-001 [&lt;ulink linkID="2056157" linkType="Reference"&gt;2056157&lt;/ulink&gt;]. Later that month, the  drug was launched in the US in that setting [&lt;ulink linkID="2056485" linkType="Reference"&gt;2056485&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2015, the US FDA granted Orphan drug designation for AML [&lt;ulink linkID="1669101" linkType="Reference"&gt;1669101&lt;/ulink&gt;]. In April 2017, ivosidenib was granted Orphan designation for cholangiocarcinoma [&lt;ulink linkID="1923113" linkType="Reference"&gt;1923113&lt;/ulink&gt;]. In May 2018, the FDA granted Orphan designation for glioma [&lt;ulink linkID="2032906" linkType="Reference"&gt;2032906&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2015, the  FDA granted  Fast Track designation for the treatment of  AML that harbors an IDH1 mutation [&lt;ulink linkID="1660979" linkType="Reference"&gt;1660979&lt;/ulink&gt;], [&lt;ulink linkID="1903591" linkType="Reference"&gt;1903591&lt;/ulink&gt;]. In November 2016, the FDA had granted Fast Track designation for the treatment of patients with previously treated, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation [&lt;ulink linkID="1891136" linkType="Reference"&gt;1891136&lt;/ulink&gt;], [&lt;ulink linkID="1903591" linkType="Reference"&gt;1903591&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In February 2018, the company planned to submit  an MAA to the EMA for IDH1 mutant-positive relapsed or refractory AML in 4Q18 [&lt;ulink linkID="2005245" linkType="Reference"&gt;2005245&lt;/ulink&gt;], [&lt;ulink linkID="2005359" linkType="Reference"&gt;2005359&lt;/ulink&gt;]. In December 2018, an MAA was submitted to the EMA [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, the EMA's COMP recommended granting Orphan designation for the treatment of AML [&lt;ulink linkID="1874733" linkType="Reference"&gt;1874733&lt;/ulink&gt;]; In December 2016, the EC grantedOrphan drug status [&lt;ulink linkID="1887616" linkType="Reference"&gt;1887616&lt;/ulink&gt;]. In February 2018, the COMP recommended granting Orphan designation for the treatment of biliary tract cancer [&lt;ulink linkID="2012555" linkType="Reference"&gt;2012555&lt;/ulink&gt;]; in March 2018, the Orphan designation was granted [&lt;ulink linkID="2028500" linkType="Reference"&gt;2028500&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In June 2018, the product was being developed as a class 1 imported chemical drug in China  [&lt;ulink linkID="2040779" linkType="Reference"&gt;2040779&lt;/ulink&gt;], [&lt;ulink linkID="2049098" linkType="Reference"&gt;2049098&lt;/ulink&gt;]. In April 2019, the Taiwan Food and Drug Administration (TFDA)  awarded ivosidenib the NDA filing priority review status.  In June 2019, an NDA was submitted to the  TFDA for  ivosidenib    for treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible IDH1 mutation [&lt;ulink linkID="2158280" linkType="Reference"&gt;2158280&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SAFETY INFORMATION&lt;/subtitle&gt;The US label carries a black box warning highlighting the risk of differentiation syndrome following drug use [&lt;ulink linkID="2056174" linkType="Reference"&gt;2056174&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Monotherapy studies&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In December 2016, a randomized, double-blind, placebo-controlled, interventional, parallel assignment, phase III trial (&lt;ulink linkID="281987" linkType="Protocol"&gt;NCT02989857&lt;/ulink&gt;; AG120-C-005; CLARIDHY) was initiated in the  US, Europe and South Korea in previously-treated patients (expected n = 186) with  nonresectable or metastatic advanced cholangiocarcinoma with an IDH1 mutation. At that time, the trial was expected to complete in August 2020 [&lt;ulink linkID="1885696" linkType="Reference"&gt;1885696&lt;/ulink&gt;], [&lt;ulink linkID="1892568" linkType="Reference"&gt;1892568&lt;/ulink&gt;]; in February 2017, enrollment was underway [&lt;ulink linkID="1903591" linkType="Reference"&gt;1903591&lt;/ulink&gt;]. In February 2019, enrollment was completed [&lt;ulink linkID="2119865" linkType="Reference"&gt;2119865&lt;/ulink&gt;]; the overall endpoint was PFS [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;]. In May 2019, the trial met its primary endpoint with a significant improvement in  PFS compared with    placebo  [&lt;ulink linkID="2154688" linkType="Reference"&gt;2154688&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In February 2019, a Groupe Francophone des Myelodysplasies-sponsored interventional, single group assignment, a single-arm phase II multicenter study (&lt;ulink linkID="336837" linkType="Protocol"&gt;NCT03503409&lt;/ulink&gt;; IDIOME-STUDY) of AG-120 was initiated in patients (expected n = 68) with IDH1 mutated myelodysplastic syndrome and AML in the US and France. The primary endpoint was overall hematological response. At that time, the study was expected to complete in January 2024 [&lt;ulink linkID="2137586" linkType="Reference"&gt;2137586&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In March 2019, results from a pooled analysis of three studies (NCT02579707, AG120-C-004; NCT02074839, AG120-C-001; NCT02073994, AG120-C-002) were presented at the 2019 ASCPT Annual Meeting in Washington DC.   In the primary analysis, from 314 subjects (all three studies), a total of 2377 triplicate ECG measurements were included which corresponded to approximately 85% of the full QT dataset. For the Fridericia correction (p = 0.48 for baseline only; p = 0.26 for all time points) among QT, Bazett's formula and Fridericia's formula (QTcF), the regression line slope became non-significant. No evidence of hysteresis was seen in the graphical inspection of the mean profiles for ivosidenib plasma concentration and QTcF [&lt;ulink linkID="2129037" linkType="Reference"&gt;2129037&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt;In June 2018, clinical data from an open-label, randomized, two-period, cross-over, phase I study  (&lt;ulink linkID="243735" linkType="Protocol"&gt;NCT02579707&lt;/ulink&gt;) which evaluated the effect of food on pharmacokinetics of ivosidenib  in 30 healthy subjects were presented at the 23rd EHA Annual Congress in Stockholm, Sweden. Patients received single oral dose of ivosidenib (two 250 mg tablets), following either a 10 h overnight fast (period-1) or 30 min after the start of a high-fat breakfast (period 2) and the patients crossed-over following a &amp;gt;/= 25 days washout period. Following administration in the high-fat fed and fasted conditions, ivosidenib 500 mg was readily absorbed, with similar Tmax of 3 and 3.03 h post dose respectively. After reaching Cmax, there was a decline in plasma concentrations in a multiphasic manner with similar T1/2 values of 53.2 and 55.4 h in fed and fasted condition, respectively. Increase in Cmax was large in the fed compared with the fasted condition, while the extent of exposure was higher following dosing in the fed versus fasted condition. Overall, a single oral dose of 500 mg ivosidenib administered in the fed and fasted conditions was appeared to be safe and well-tolerated [&lt;ulink linkID="2045538" linkType="Reference"&gt;2045538&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2018, Massachusetts General Hospital sponsored investigator led open-label, non-randomized,  single-group-assigned, phase I (&lt;ulink linkID="343797" linkType="Protocol"&gt;NCT03564821&lt;/ulink&gt;; 18-123) study to evaluate  Ivosidenib as maintenance therapy in patients (expected n = 22) with  IDH1-mutant myeloid neoplasms (including IDH1-mutant acute myeloid leukemia, myelodysplastic syndrome or chronic myelomonocytic leukemia) following allogeneic stem cell transplantation was to be initiated in July 2018 in collaboration with Agios Pharmaceuticals. At that time, the trial was expected to complete in July 2024 [&lt;ulink linkID="2050118" linkType="Reference"&gt;2050118&lt;/ulink&gt;]. In January 2019,  the trial was initiated [&lt;ulink linkID="2050118" linkType="Reference"&gt;2050118&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017, an open-label, non-randomized, single-dose, phase I study (&lt;ulink linkID="312623" linkType="Protocol"&gt;NCT03282513&lt;/ulink&gt;; AG120-C-012) was initiated in the US in patients (expected n = 32) with mild or moderate hepatic impairment or normal hepatic function, to evaluate the pharmacokinetics, safety, and tolerability of the drug. At that time, the trial was to complete in February 2018 [&lt;ulink linkID="1974147" linkType="Reference"&gt;1974147&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2017, clinical data from a single dose, open label study (&lt;ulink linkID="234057" linkType="Protocol"&gt;NCT02489513&lt;/ulink&gt;) in 8 healthy male subjects were presented at 118th ASCPT Annual Meeting in Washington DC. Healthy male subjects received 500 mg po dose of [14 C] AG-120 (approximately microcurie/subject) in the morning. The Cmax was 990, 1160 and 635 ng/ml, respectively; T max was 4, 5 and 5 h, respectively; AUC (2 to 96 h) was 79300, 108000 and 79200 ng h/ml, respectively; t 1/2 was 53.4, 71.7 and 64.9 h, respectively, for AG-120 (plasma) and radioactivity (plasma and blood). Of eight subjects, two (25%) had reported six adverse events, all of mild to moderate severity [&lt;ulink linkID="1909489" linkType="Reference"&gt;1909489&lt;/ulink&gt;]. &lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;In March 2017, an interventional, open-label, single-dose, phase I trial (&lt;ulink linkID="290073" linkType="Protocol"&gt;NCT03071770&lt;/ulink&gt;; AG120-C-006) began in the US in healthy, adult male Japanese and Caucasian subjects (n = 60). The trial completed in September 2017 [&lt;ulink linkID="2135580" linkType="Reference"&gt;2135580&lt;/ulink&gt;]. In March 2019, results were presented at 2019 ASCPT Annual Meeting in Washington DC. For Japanese subjects, distribution of AUC and Cmax values generally fell within the range of values for Caucasian subjects. In both Japanese and Caucasian subjects, ivosidenib was steadily absorbed with a median Tmax of 3 to 4 h; however, plasma concentrations declined slowly after reaching Cmax with a mean t1/2 values of 40.9 to 46 h in Japanese and 45.8 to 64 h in Caucasian subjects. Overall, one Japanese subject of 250 mg cohort reported a grade 2 adverse event (AE) of an upper respiratory tract infection and one Caucasian subject of 1000 mg cohort reported a grade 1 AE of migraine headache   [&lt;ulink linkID="2129090" linkType="Reference"&gt;2129090&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2014, a multicenter, open-label, dose-escalation, safety, pharmacokinetic, pharmacodynamic, and clinical activity phase I study (&lt;ulink linkID="175666" linkType="Protocol"&gt;NCT02074839&lt;/ulink&gt;; AG120-C-001) was  initiated in the US and France in patients (expected n = 266)  with advanced hematologic malignancies with an IDH1 mutation. At that time, the study was expected to be completed in March 2016. The first portion of the trial was  a dose-escalation phase where cohorts would receive ascending oral doses to determine MTD and recommended phase II dose; the second portion of the study was a dose expansion phase where four cohorts would receive the receommended phase II dose [&lt;ulink linkID="1533007" linkType="Reference"&gt;1533007&lt;/ulink&gt;]; later that month, first patient was enrolled  and dosed in the phase I portion [&lt;ulink linkID="1536547" linkType="Reference"&gt;1536547&lt;/ulink&gt;], [&lt;ulink linkID="1538266" linkType="Reference"&gt;1538266&lt;/ulink&gt;]. In November 2014, clinical data were presented at the 26th EORTC-NCI-AACR Symposium in Barcelona, Spain. Of 14 evaluable patients, 7 responded to the drug, including 4 complete responses (n = 1 at each dose; 100 mg bid, 300, 500, and 800 mg qd) and 2 marrow complete responses (500 mg qd). There were also six stable diseases (100 to 500 mg doses). Treatment with ivosidenib showed substantial lowering of 2-HG to levels observed in healthy volunteers consistently aligned with preclinical assays [&lt;ulink linkID="1611754" linkType="Reference"&gt;1611754&lt;/ulink&gt;], [&lt;ulink linkID="1614459" linkType="Reference"&gt;1614459&lt;/ulink&gt;]. In June 2015, further clinical data were presented at the 20th EHA Congress in Vienna, Austria. Ivosidenib treatment showed the overall response rate of 31% including eight complete remissions. Stable disease and progressive was observed in 27 and 8 patients, respectively [&lt;ulink linkID="1670411" linkType="Reference"&gt;1670411&lt;/ulink&gt;] [&lt;ulink linkID="1669821" linkType="Reference"&gt;1669821&lt;/ulink&gt;]. Further data were presented at the same conference.  Ivosidenib showed a long plasma half-life of &amp;gt; 32 h and steady state was reached at cycle 1 day 15. The mean plasma 2-hydroxyglutarate (2-HG) levels were significantly reduced (up to 99.7% inhibition) to levels seen in healthy volunteers after multiple doses of ivosidenib, at 100 mg bid and AUC (0 to 10 h) value of 15.5 h.microg/ml [&lt;ulink linkID="1670422" linkType="Reference"&gt;1670422&lt;/ulink&gt;].  In December 2015, further data were presented at the 57th ASH Annual Meeting and Exposition in Orlando, FL. Complete response, partial response, stable disease and progressive disease were seen in 15, 1, 51 and 9% of the patients, respectively. Objective response rate was seen in 35% of the patients and at the time of presentation, MTD was not yet reached [&lt;ulink linkID="1718379" linkType="Reference"&gt;1718379&lt;/ulink&gt;]. At the same conference, further data were presented.  A mean half-life, low apparent clearance and volume of distribution of 117 h, 1.74 l/h and 215 l, respectively were observed for ivosidenib [&lt;ulink linkID="1718450" linkType="Reference"&gt;1718450&lt;/ulink&gt;]. In January 2016, similar clinical data were presented at the 34th Annual JP Morgan Healthcare Conference in San Francisco, CA. In relapsed/refractory AML patients (n = 300), median duration of response was 5.6 months with a maximum response recorded of &amp;gt; 14 months. Dose-escalation was completed and phase I expansion ongoing (n = 25 x 3 cohorts; n = 125) [&lt;ulink linkID="1726773" linkType="Reference"&gt;1726773&lt;/ulink&gt;]. In August 2016, similar data were presented at 24th EFMC-ISMC Symposium in Manchester, UK [&lt;ulink linkID="1791691" linkType="Reference"&gt;1791691&lt;/ulink&gt;], [&lt;ulink linkID="1703096" linkType="Reference"&gt;1703096&lt;/ulink&gt;]. In December 2016, further data were presented at the 58th ASH Annual Meeting and Exposition in San Diego, CA. Day 30 and 60 all-cause mortality rates were 12 and 16%, respectively. In relapsed/refractory AML and overall patients, complete response (CR), CR with incomplete neutrophil recovery/CR with incomplete platelet recovery, partial response, marrow CR/morphologic leukemia-free state was achieved by 10 and 14, 8 and 8, 1 and 2, and 2 and 6 patients, respectively. In CR and non-CR patients, numbers of subjects with longitudinal variant allele frequency (VAF) was 14 and 53, respectively; and number of subjects with mutation clearance was 5 and 2, respectively. At that time, enrollment in dose-expansion phase was ongoing [&lt;ulink linkID="1881665" linkType="Reference"&gt;1881665&lt;/ulink&gt;] [&lt;ulink linkID="1882410" linkType="Reference"&gt;1882410&lt;/ulink&gt;]. By February 2017, four expansion cohorts had been added to the trial. The first (1), second (2), third (3) and fourth (4) cohorts would assess the drug in patients with (1) AML in second or later relapse,  refractory to second-line induction or reinduction treatment, or  relapsed after allogeneic transplantation, (2) untreated AML patients, (3) other non-AML IDH1 mutant-positive relapsed or refractory advanced hematologic malignancies and (4) relapsed IDH1 mutant-positive AML not eligible for the first arm or standard of care chemotherapy; in cohorts 1, 2 and 3, the number of patients expected to be enrolled was 125, 25 and 25, respectively [&lt;ulink linkID="1903591" linkType="Reference"&gt;1903591&lt;/ulink&gt;]. In December 2017, further data were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. In primary R/R AML set, complete remission (CR) + CR with partial hematologic recovery (CRh), CR and CRh rate was achieved by 38, 27 and 11 patients, respectively; median time to CR + CRh and CR was 2.7 and 2.8 months, respectively; and the median duration of CR+CRh and CR was 8.2 and 9.3 months, respectively. Overall response rate was achieved by 82 patients, and the median time and duration to first response was 1.9 and 6.5 months, respectively. In CR, CRh, non-CR/CRh responders, non-responders and overall population (n = 27, 11, 14, 73 and 125, respectively), the incidence rate (reported as 100 patients/month) of all grade febrile neutropenia was reported by 2.6, 3.8, 3.9, 14.2 and 6.9%, respectively; and grade &amp;gt;/= 3 infections was 2.6, 6.4, 14.4, 23.0 and 11.5%, respectively [&lt;ulink linkID="1988486" linkType="Reference"&gt;1988486&lt;/ulink&gt;]. In December 2017, further results were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. Ivosidenib treatment decreased mIDH1 VAF in bone marrow mononuclear cells and neutrophils from patients who attained best overall response of CR/CRh (R/R AML). Among patients with R/R AML, best response was CR+CRh, CR and h in 21, 29 and 0% of patients with IDH1-mutation clearance (MC) and 79, 72 and 100% in those without IDH1-MC, respectively; in untreated AML patients, best response was CR+CRh, CR and h in 56, 60 and 50% of patients with IDH1-MC and 44, 40 and 50% in those without IDH1-MC, respectively [&lt;ulink linkID="1988772" linkType="Reference"&gt;1988772&lt;/ulink&gt;]. In December 2017, further data were reported from an efficacy analysis of 34 untreated AML patients not eligible for standard of care therapies  and 12 patients with MDS  in expansion cohorts whose starting dose was 500 mg daily. Data from 34 untreated AML patients demonstrated a 55.9% ORR and a CR rate of 20.6% and the median duration of response was 9.2 months.  As of February 2018, the median duration of CR was still to be reached. Results from the 12 MDS patients demonstrated a 91.7% ORR and a CR rate of 41.7% [&lt;ulink linkID="2005359" linkType="Reference"&gt;2005359&lt;/ulink&gt;]. At that time, the trial was expected to complete in May 2021 [&lt;ulink linkID="1533007" linkType="Reference"&gt;1533007&lt;/ulink&gt;]. In June 2018, further data from a cohort of 179 R/R AML patients were presented at the 23rd EHA Annual Congress in Stockholm, Sweden. The CR + CRh rate was 31.8%, including CR in 24.0% of patients. The median duration of CR+CRh was 8.2 months, and the duration of CR was 10.1 months. The overall response rate was 41.9%. A total of 19 patients reported IDH differentiation syndrome (IDH-DS), including grade &amp;gt;/= 3 IDH-DS in 9 patients. The proportion of patients who were transfusion dependent at baseline who demonstrated a CR and achieved platelet and RBC transfusion independence was 100% and 88.2%, respectively. The proportion of patients who were transfusion dependent at baseline who demonstrated a CRh and achieved platelet and RBC transfusion independence was 75% and 77.8%, respectively [&lt;ulink linkID="2045657" linkType="Reference"&gt;2045657&lt;/ulink&gt;].   In June 2018, further data were presented at the 54th ASCO Annual Meeting in Chicago, IL. AUC (0 to 8h), AUC (0 to 24h), Cmax, T max, apparent clearance at steady sate [SS], accumulation ratio (Racc) based on AUC and Racc based on Cmax was 43163 h.ng/ml, 115729 h.ng/ml, 6505 ng/ml, 3 h, 4.32 lh, 1.88 and 1.45, respectively. Concomitant administration of weak CYP3A4 inhibitors or inducers did not affect ivosidenib clearance, although moderate/strong CYP3A4 inhibitors decreased ivosidenib clearance and increased SS exposure (AUC (0 to 24h) and Cmax at SS by approximately 56 and 47%) [&lt;ulink linkID="2040009" linkType="Reference"&gt;2040009&lt;/ulink&gt;]. At the same conference, updated safety and efficacy data were presented. In the R/R AML 500 mg set (n = 179), grade &amp;gt;/= 3 leucocytosis, ECG QT prolongation and IDH differentiation syndrome were reported by 14, 18 and 19 patients, respectively. Median time to complete remission (CR)/CR with partial hematologic recovery (CRh), duration of CR/CRh, CR rate, median time to CR, duration of CR, CRh rate, overall response rate, median time to first response, duration of response was 57%, 2 months, 8.2 months, 43%, 2.8 months, 10.1 months, 14%, 3.6 months, 1.9 months and 6.5 months, respectively. Exposure-adjusted incidence of febrile neutropenia and grade &amp;gt;/= 3 infections was 2 and 2.6% in CR; 3.7 and 6.4% in CRh; 6.1 and 13.1% in non-CR/CRh responders; 12.1 and 21.3% in non-responders and 5.9 and 10.2% in overall population, respectively [&lt;ulink linkID="2040055" linkType="Reference"&gt;2040055&lt;/ulink&gt;], [&lt;ulink linkID="2040854" linkType="Reference"&gt;2040854&lt;/ulink&gt;]. In December 2018, further data in IDH1-mutant untreated patients were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. CR rate was 26.5%, CR+ CRh rate was 41.2%, and the ORR was 58.8%. The median durations of CR, CR+CRh, and ORR were not estimable. Among the patients who were transfusion dependent at baseline, 38.1% became transfusion independent for &amp;gt;/= 56 consecutive days on treatment [&lt;ulink linkID="2098282" linkType="Reference"&gt;2098282&lt;/ulink&gt;],  [&lt;ulink linkID="2101035" linkType="Reference"&gt;2101035&lt;/ulink&gt;]. Further data for the patients with R/R MDS in expansion arm (n = 9) and in dose escalation whose starting dose was 500 mg qd (n = 3) were presented at the same conference. In R/R MDS patients receiving 500 mg (n = 12), ORR was 91.7%; median time to first response was 1.8 months and median duration of response was 21.4 months. Complete response rate was 42.7%, median time to CR was 1.9 months and duration was CR was not estimable. The percentages of patients who remained in CR and response at 12 months were 60.0% and 61.4%, respectively. Of five patients who were transfusion dependent at baseline, four became transfusion independent for at least 56 days on treatment. There were no grade &amp;gt;/= 3 leukocytosis and grade &amp;gt;/= 3 ECG QT prolonged   [&lt;ulink linkID="2098105" linkType="Reference"&gt;2098105&lt;/ulink&gt;] [&lt;ulink linkID="2101035" linkType="Reference"&gt;2101035&lt;/ulink&gt;].  In June 2019, further data in patients with IDH1-mutant newly-diagnosed AML were presented at the 55th ASCO Annual Meeting in Chicago, IL. As of 02 Nov 2018, 21% of patients remained on treatment and 9% had discontinued treatment for allogeneic stem cell transplant. Median duration of ivosidenib exposure was 4.3 months. Most of the AEs reported were of grade 1–2 and were considered unrelated to treatment. In a total of 18 and 9% of patients IDH differentiation syndrome (DS) and grade &amp;gt;/=3 was observed, respectively; in three patients ivosidenib treatment was held due to DS. In six patients QT prolongation was observed. A total of 43% of patients who were transfusion dependent at baseline became transfusion independent for &amp;gt;/=56 consecutive days on treatment [&lt;ulink linkID="2161231" linkType="Reference"&gt;2161231&lt;/ulink&gt;] [&lt;ulink linkID="2158776" linkType="Reference"&gt;2158776&lt;/ulink&gt;]. In June 2019, results were presented at the 24th EHA Annual Congress in Amsterdam, Netherlands. With ivosidenib 500 mg, the overall response rate was 91.7% (median duration 21.4 months) with best responses including CR (41.7%), partial response (8.3%), modified CR (41.7%) and progressive disease (8.3%). The median time to first reponse was 1.9 months with duration of response of 21.4 months. Four out of five patients who were transfusion-dependent at baseline became transfusion independent for &amp;gt;/=56 days on treatment. IDH1 mutation clearance was noted in two patients. Investigator-reported AE of interest was IDH differentiation syndrome of grade 2 reported in one patient [&lt;ulink linkID="2164686" linkType="Reference"&gt;2164686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, the company planned to initiate clinical studies in the "near future" [&lt;ulink linkID="1330796" linkType="Reference"&gt;1330796&lt;/ulink&gt;].   In November 2013, the company was planning to submit an IND and initiate phase I trials in patients with advanced solid and hematological malignancies that carry an IDH1 mutation  in early 2014 [&lt;ulink linkID="1497451" linkType="Reference"&gt;1497451&lt;/ulink&gt;]. By January 2014, an IND had been filed and first-in-human phase I studies remained on track for early 2014. At that time, the company planned to conduct a phase I dose-escalation trial in hematological malignancies, with possible expansion to include patients with acute myeloid leukemia,    myelodysplastic syndrome and myeloproliferative disorders, and a phase I dose-escalation trial in solid tumors, with possible expansion to include patients with intrahepatic cholangiocarcinoma,  chondrosarcoma, glioma and others. The trials were to have a '3 + 3' design and patients were to be IDH1-mutant positive. The study endpoints included the maximum tolerated dose, safety, pharmacokinetics, assessment of 2-hydroxyglutarate (2-HG) levels, differentiation and efficacy [&lt;ulink linkID="1517655" linkType="Reference"&gt;1517655&lt;/ulink&gt;],  [&lt;ulink linkID="1524480" linkType="Reference"&gt;1524480&lt;/ulink&gt;]. By December 2013, the FDA had accepted the IND filing [&lt;ulink linkID="1532208" linkType="Reference"&gt;1532208&lt;/ulink&gt;]. In March 2014, an open-label, multicenter, dose-escalation, phase I trial (&lt;ulink linkID="175722" linkType="Protocol"&gt;NCT02073994&lt;/ulink&gt;; AG120-C-002) was initiated in the US and France in patients (expected n = 170) with advanced solid tumors that habor  an IDH 1 mutation, including cholangiocarcinoma, chondrosarcoma and glioma    to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity following oral administration of ivosidenib. The trial was expected to complete in March 2016 [&lt;ulink linkID="1531603" linkType="Reference"&gt;1531603&lt;/ulink&gt;]. In March 2014, the first patient was dosed [&lt;ulink linkID="1538266" linkType="Reference"&gt;1538266&lt;/ulink&gt;]. In June 2014, Translational Genomics Research Institute (TGen) in collaboration with Scottsdale Healthcare  initiated the trial in solid tumor patients including glioma and bile duct cancer [&lt;ulink linkID="1570655" linkType="Reference"&gt;1570655&lt;/ulink&gt;]. In November 2015, clinical data were presented at the 27th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. A total of 62 patients with advanced solid tumors with a IDH mutation were treated with 100 mg bid and 300, 400, 500, 600, 800, 900 and 1200 mg qd po of ivosidenib in 28 day cycles. Treatment was well tolerated with no MTD recorded, although the MTD was not reached. At least one adverse event occurred in 89% (n = 55) of patients, serious adverse events in 29% (n = 18) of patients, and discontinuation of treatment in 60% (n = 37) of patients. There were no treatment-related deaths. The best overall response was seen in the cholangiocarcinoma patient cohort with one occurrence of partial response. The overall clinical benefit rate was 37% [&lt;ulink linkID="1711181" linkType="Reference"&gt;1711181&lt;/ulink&gt;], [&lt;ulink linkID="1711344" linkType="Reference"&gt;1711344&lt;/ulink&gt;], [&lt;ulink linkID="1712580" linkType="Reference"&gt;1712580&lt;/ulink&gt;]. In January 2016,  enrollment was complete [&lt;ulink linkID="1983704" linkType="Reference"&gt;1983704&lt;/ulink&gt;]. In January 2016, similar clinical data were presented at the 34th Annual JP Morgan Healthcare Conference in San Francisco, CA.Tumor volume was reduced in some glioma patients. The expansion phase of the trial was ongoing [&lt;ulink linkID="1726773" linkType="Reference"&gt;1726773&lt;/ulink&gt;]. In November 2016, the first data from the dose expansion cohorts of the study were reported. The glioma data were presented at the Society for Neuro-Oncology (SNO) Annual Meeting in Scottsdale, AZ and chondrosarcoma data were presented on the 'previous week' at the annual meeting of the Connective Tissue Oncology Society (CTOS) in Lisbon, Portugal. Data on glioma patients demonstrated that AG-120 was found to be well-tolerated with a favorable safety profile in a safety analysis conducted for all the 66 treated patients. The efficacy data from 65 patients were reported;  41 (63%) patients had stable disease, including 27 patients with non-enhancing disease; median treatment duration for non-enhancing glioma was 8.1 months (ranging from 1.4 - 17.8 months); Volumetric analysis conducted showed a stabilization or a decrease in tumor growth rate compared to the pre-treatment rate in 64% (n=14 of 22) glioma patients.  The data analyzed from 21 chondrosarcoma in the dose escalation (n=12) and expansion cohorts (n=9) and 7 remained on treatment. Among 20 response-evaluable patients, 11 (55%) experienced stable disease as their best response; the 3-month progression-free survival rate was 58%. The baseline plasma levels of the oncometabolite D-2-hydroxyglutarate (2-HG) were elevated above the healthy volunteer range and treatment with AG-120 resulted in significant reduction of plasma 2-HG compared to baseline; up to 99.7% tissue 2-HG reduction was documented in paired biopsies obtained from 3 patients. At that time, the trial was expected to complete in August 2017 [&lt;ulink linkID="1876635" linkType="Reference"&gt;1876635&lt;/ulink&gt;]. Further data were presented at the same conference. Grade 1/2 headache (4.5% grade 3), nausea, vomiting, fatigue, and diarrhea were the frequently reported adverse events (&amp;gt;10%) regardless of attribution [&lt;ulink linkID="1892327" linkType="Reference"&gt;1892327&lt;/ulink&gt;].  In June 2017, further data were presented at 53rd ASCO meeting in Chicago, IL. At ivosidenib 500 and 1200 mg (March 10, 2017, data cut-off) , 4 of 73 patients with cholangiocarcinoma  experienced grade &amp;gt;/= 3  drug-related AEs like fatigue, blood alkaline increased, and fatigue and blood phosphorus decreased, respectively. In patients treated with ivosidenib (&amp;lt;500, 500 and &amp;gt; 500 mg qd), progressive response (PR) was achieved by in 1, 3 and 0 patients, respectively. The satble disease rate was 56%, with   PFS rates at 6 and 12 months of  38.5 and 20.7%, respectively. The median PFS was 3.8 months [&lt;ulink linkID="1932343" linkType="Reference"&gt;1932343&lt;/ulink&gt;], [&lt;ulink linkID="1934018" linkType="Reference"&gt;1934018&lt;/ulink&gt;]. Further data were presented at same conference.  At ivosidenib 500 mg qd, the average 2-HG inhibition was 80%, while at AG-120 &amp;gt; 500 mg, no further increase in 2-HG inhibition was observed. No significant effect of patients’ intrinsic factors (age, sex, weight, serum albumin, liver function, renal function, basal metabolic index, basal serum albumin and total protein) on ivosidenib plasma clearance was observed [&lt;ulink linkID="1932148" linkType="Reference"&gt;1932148&lt;/ulink&gt;], [&lt;ulink linkID="1934018" linkType="Reference"&gt;1934018&lt;/ulink&gt;]. In October 2017, further clinical data were presented at the 29th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, PA. In patients with partial response (at cycle 7 day1) and stable disease (at cycle 3 day1), AG-120 treatment showed increase in cholangiolar histology (&amp;gt;/= 20%) and showed reduction in the volume of cytoplasm when compared with baseline. Increased cholangiolar histology seems to be associated with increased progression free survival. Patients with increase in cholangiolar histology showed upregulation of genes associated with mature liver cells [&lt;ulink linkID="1975447" linkType="Reference"&gt;1975447&lt;/ulink&gt;]. In November 2017,  updated data from the dose expansion cohort of the study evaluating ivosidenib in patients with progressive low grade IDH1 mutation glioma were presented at the Society for Neuro-Oncology Annual Meeting in San Francisco, CA. As of the May 2017 data cut off, 35 patients (11 from escalation, 24 from expansion) with non-enhancing glioma had been treated with single agent ivosidenib. The median duration of treatment was 16 months with 51% of patients (n = 18) remaining on treatment. The median duration of last systemic therapy was 9.6 months. The efficacy data from all 35 non-enhancing glioma patients as of the data cut-off showed that two patients had a minor response by investigator assessment according to the Response Assessment in Neuro-Oncology for low grade glioma (RANO-LGG) and 29 patients had stable disease. The median progression free survival (PFS) for all non-enhancing patients was 13 months, and the median PFS for Grade 2 patients (n = 24) was not reached. In patients from the expansion arm (n = 24), the average 6-month tumor growth was 24% prior to treatment and 11% following ivosidenib therapy  [&lt;ulink linkID="1983704" linkType="Reference"&gt;1983704&lt;/ulink&gt;]. Further data from 35 non-enhancing glioma patients were presented at the same conference. Diarrhea (26%), headache (26%), nausea (20%), anemia (17%), neutrophil decrease (17%), and vomiting (17%) were frequent adverse events (AEs) of grade 1 to 2. Grade 3 to 4 adverse events (AEs) were reported by seven patients, with no dose reduction due to AEs; most frequent was hypophosphatemia (n = 2; unrelated). Patients remained on AG-120 for &amp;gt;/= 1 year were 63% [&lt;ulink linkID="1987239" linkType="Reference"&gt;1987239&lt;/ulink&gt;]. By February 2018, enrollment was complete in the 4 expansion cohorts of 25 patients each in:  low-grade glioma with at least 6 months of prior scans to assess volumetric changes; second-line cholangiocarcinoma;  high-grade or metastatic chondrosarcoma;  and, other advanced solid tumors with an IDH1 mutation [&lt;ulink linkID="2005359" linkType="Reference"&gt;2005359&lt;/ulink&gt;]. In June 2018, further data were presented at the 54th ASCO Annual meeting in Chicago, IL.  Ivosidenib showed good oral exposure, rapidly absorption, and plasma levels declined bi-exponentially after peaking, with a mean terminal half-life of 40 to102 h after qd dose. In patients with cholangiocarcinoma and chondrosarcoma, ivosidenib exhibited robust, persistent 2-HG inhibition in both plasma and tumor. No intrinsic patient factors assessed had an effect on ivosidenib exposure   [&lt;ulink linkID="2039430" linkType="Reference"&gt;2039430&lt;/ulink&gt;]. In July 2018, the trial was expected to complete in June 2021 [&lt;ulink linkID="1531603" linkType="Reference"&gt;1531603&lt;/ulink&gt;]. In February 2019, the trial was ongoing [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Combination therapy studies&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In  February 2018, the company planned to support, in conjunction with Celgene, the initiation of an intergroup-sponsored, global, registration-enabling, phase III trial (HO150; HOVON-150) combining ivosidenib or &lt;ulink linkID="86597" linkType="Drug"&gt;enasidenib&lt;/ulink&gt; with standard induction and consolidation chemotherapy, with a primary endpoint of event-free survival, in frontline AML patients with an IDH1 (expected n = 500) or IDH2 (expected n = 500) mutation in 4Q18 [&lt;ulink linkID="2005245" linkType="Reference"&gt;2005245&lt;/ulink&gt;], [&lt;ulink linkID="2005359" linkType="Reference"&gt;2005359&lt;/ulink&gt;], [&lt;ulink linkID="2030845" linkType="Reference"&gt;2030845&lt;/ulink&gt;], [&lt;ulink linkID="2089652" linkType="Reference"&gt;2089652&lt;/ulink&gt;]. In February 2019, the registration-enabling, multicenter, double-blind, randomized, placebo-controlled, phase III trial (&lt;ulink linkID="370619" linkType="Protocol"&gt;NCT03839771&lt;/ulink&gt;; HO150; 2018-000451-41; HOVON150AML) was expected to begin later that month in patients (expected  n = 968) with newly diagnosed AML or MDS with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy. The primary endpoint was event-free survival approximately up to 60 months following first patient enrollment. At that time, the trial was expected to complete in February 2033   [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;], [&lt;ulink linkID="2127910" linkType="Reference"&gt;2127910&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2015, the company planned to initiate a global registration program in hematologic malignancies harboring an IDH1 mutation  [&lt;ulink linkID="1634420" linkType="Reference"&gt;1634420&lt;/ulink&gt;]. In June 2017, a   multicenter, double-blind, randomized, placebo-controlled, phase III study (&lt;ulink linkID="300262" linkType="Protocol"&gt;NCT03173248&lt;/ulink&gt;; AG120-C-009; CTR20181920; AGILE) of ivosidenib in combination with &lt;ulink linkID="37370" linkType="Drug"&gt;azacitidine&lt;/ulink&gt; in adults (expected n = 392) with previously untreated patients with AML with an IDH1 mutation who were not eligible for intensive chemotherapy began in the US, South America, Europe, Canada, Israel, Japan, Korea, Mexico and Taiwan with the primary endpoint of overall survival. At the time the trial was due to complete in June 2022 [&lt;ulink linkID="1944055" linkType="Reference"&gt;1944055&lt;/ulink&gt;]. In February 2018, enrollment was expected to complete enrollment in 2021 [&lt;ulink linkID="2005359" linkType="Reference"&gt;2005359&lt;/ulink&gt;]. In June 2018, study design of a phase III, multicenter, randomized, placebo-controlled study (AGILE) was presented at 54th ASCO Annual Meeting in Chicago, IL. Patients (n = 392, recruited) would be randomized (1:1) to receive either ivosidenib (500 mg qd po) + azacitidine (75 mg/m2 sc iv) or matched placebo po + azacitidine 75 mg/m2 sc iv for 28-cycles. The primary endpoint was overall survival and study had detected with 80% of power a hazard ratio of 0.71 with one-alpha of 0.025. The secondary end points were event-free survival, rate of complete response (CR), rate of CR + CRh and overall response rate. At the time of presentation AGILE was currently enrolling patients at participating sites globally [&lt;ulink linkID="2044502" linkType="Reference"&gt;2044502&lt;/ulink&gt;] [&lt;ulink linkID="2041256" linkType="Reference"&gt;2041256&lt;/ulink&gt;]. In June 2018, a clinical trial application of AGILE was filed in China  [&lt;ulink linkID="2040779" linkType="Reference"&gt;2040779&lt;/ulink&gt;]. In September 2018, approval to conduct  the trial was obtained in China [&lt;ulink linkID="2073643" linkType="Reference"&gt;2073643&lt;/ulink&gt;]; in May 2019, the trial was planned in China [&lt;ulink linkID="2149118" linkType="Reference"&gt;2149118&lt;/ulink&gt;]. In October 2018, recruitment was ongoing [&lt;ulink linkID="1944055" linkType="Reference"&gt;1944055&lt;/ulink&gt;]. In November 2018, the company reached agreement with the FDA that event free survival was an acceptable primary endpoint. At that time,  enrollment was expected to complete in 2020 [&lt;ulink linkID="2089652" linkType="Reference"&gt;2089652&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I and II&lt;/subtitle&gt;In March 2018, an investigator-sponsored, open-label, dose-escalation and dose-expansion, single-group assigned, phase I/II trial (&lt;ulink linkID="333153" linkType="Protocol"&gt;NCT03471260&lt;/ulink&gt;; 2017-0490) was initiated in the US, in patients (expected n = 48)  with relapsed  or refractory   AML with an IDH1 mutation, to assess the safety and efficacy of ivosidenib in combination with &lt;ulink linkID="70895" linkType="Drug"&gt;venetoclax&lt;/ulink&gt;. At that time, the trial was expected to complete in September 2020 [&lt;ulink linkID="2017713" linkType="Reference"&gt;2017713&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, the company was planning to initiate a  randomized, open-label, perioperative, phase I   study (&lt;ulink linkID="319714" linkType="Protocol"&gt;NCT03343197&lt;/ulink&gt;; AG120-881-C-001) with ivosidenib and &lt;ulink linkID="96690" linkType="Drug"&gt;AG-881&lt;/ulink&gt; in low-grade glioma patients with progressive disease (expected n = 45) to further investigate the effects on brain tumor tissue in April 2018. Patients would be randomized to receive ivosidenib or AG-881 for 4 weeks prior to surgery. The trial was expected to complete in September 2020 [&lt;ulink linkID="1977016" linkType="Reference"&gt;1977016&lt;/ulink&gt;], [&lt;ulink linkID="1983704" linkType="Reference"&gt;1983704&lt;/ulink&gt;],  [&lt;ulink linkID="1994678" linkType="Reference"&gt;1994678&lt;/ulink&gt;].  In March 2018, the window trial was initiated   [&lt;ulink linkID="1994678" linkType="Reference"&gt;1994678&lt;/ulink&gt;], [&lt;ulink linkID="2030845" linkType="Reference"&gt;2030845&lt;/ulink&gt;]. In February 2019, the trial was ongoing [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2016, an open-label, phase I/II trial (phase Ib dose escalation plus phase II randomized stages) (&lt;ulink linkID="252932" linkType="Protocol"&gt;NCT02677922&lt;/ulink&gt;; AG-221-AML-005) of once daily &lt;ulink linkID="86597" linkType="Drug"&gt;enasidenib&lt;/ulink&gt; or ivosidenib, in combination with &lt;ulink linkID="37370" linkType="Drug"&gt;azacitidine&lt;/ulink&gt;, began in patients (n = 150) with newly diagnosed AML with an IDH2 and/or IDH1 mutation ineligible for intensive chemotherapy. The primary endpoint was safety, tolerability and efficacy. At that time, the trial was expected to complete in December 2019 [&lt;ulink linkID="1747424" linkType="Reference"&gt;1747424&lt;/ulink&gt;], [&lt;ulink linkID="1736151" linkType="Reference"&gt;1736151&lt;/ulink&gt;]. By February 2017, the Celgene-conducted trial had completed the phase I component. At that time, enrollment in the phase II part was ongoing and its primary endpoint was overall response rate [&lt;ulink linkID="1903591" linkType="Reference"&gt;1903591&lt;/ulink&gt;]. In December 2017, preliminary phase Ib portion results were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. Ivosidenib was administered to IDH1 mutation-positive AML patients (n = 11) at 500 mg qd (dose-finding (n = 7) and expansion cohorts (n = 4; enrollment now closed)) in combination with azacitidine (75 mg/m2/day x 7 days/cycle sc). The trial recruited 17 adult patients (n = 6 enasidenib + azacitidine ; n = 11 ivosidenib + azacitidine) who were ineligible for intensive chemotherapy; by September 01, 2017, 11 patients remained on-study (n =  3 enasidenib + azacitidine; n= 8 (ivosidenib + azacitidine). For ivosidenib cohorts (median 3 cycles), the most common events included nausea (n = 8), constipation (n = 6), fatigue (n = 5) and diarrhea (n = 4), and treatment-related nausea (n = 6) and fatigue (n = 4); IDH-differentiation syndrome was again seen in one patient and one death was recorded although this was not treatment-related. Ivosidenib patients achieved complete response (n = 4), complete remission (n = 1), partial response (n = 1), a morphologic leukemia-free state (n = 2), and stable disease (n = 3).  Best treatment duration for ivosidenib was complete response/remission for 14 months. Results validate the use of 100 mg enasidenib + azacitidine and 500 mg ivosidenib + azacitidine for further study [&lt;ulink linkID="1988729" linkType="Reference"&gt;1988729&lt;/ulink&gt;], [&lt;ulink linkID="1990779" linkType="Reference"&gt;1990779&lt;/ulink&gt;]. In February 2018, enrollment was ongoing. The primary endpoint of the phase II portion was ORR up to approximately 30 months  [&lt;ulink linkID="2005359" linkType="Reference"&gt;2005359&lt;/ulink&gt;], [&lt;ulink linkID="1736151" linkType="Reference"&gt;1736151&lt;/ulink&gt;]. In June 2018,  interim results  from phase Ib portion  were presented at the 54th ASCO Annual meeting in Chicago, IL. The overall response rate was 78 and 67%; complete response (CR) was observed in 10 and 3; CR with incomplete hematologic or platelet recovery (CRh) observed in 5 and 0 patients; partial response in 0 and 0 patients; morphologic leukemia-free state in 3 and 1 patients; stable disease was observed 4 and 1 patients; disease progression in 0 and 1, respectively, in ivosidenib + azacitidine (n = 23) and enasidenib + azacitidine (n = 6) groups. In ivosidenib + azacitidine arm, the median time to first response and best response was 1.8 and 3.6 months, respectively, and median duration of response was not reached. IDH clearance was observed in 7 out 21 patients in ivosidenib + azacitidine arm and 3 of 6 patients in enasidenib + azacitidine group  [&lt;ulink linkID="2039857" linkType="Reference"&gt;2039857&lt;/ulink&gt;]. In June 2018, further data were presented at 23rd EHA Annual Congress in Stockholm, Sweden. In patients treated with ivosidenib + azacitidine, the most common treatment-emergent adverse events (TEAEs) including nausea, anemia and thrombocytopenia were reported by 14, 12 and 11 patients, respectively.  In ivosidenib + azacitidine group, overall response rate observed in 18 patients [&lt;ulink linkID="2045670" linkType="Reference"&gt;2045670&lt;/ulink&gt;]. By February 2019, enrollment of the phase I/II frontine combination trial had been completed [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;]. In February 2019, further data from the phase Ib portion of the trial were presented at the 17th International Symposium on Acute Leukemias in Munich, Germany. Combination treatment with ivosidenib + azacitidine produced an overall response rate of 78%, a CR+CRh rate of 65%, a CR of 57% and a 12-month survival rate of 82%. Additionally, IDH1 mutation clearance was achieved by most CR patients. Median duration of follow-up was 9.5 months (range 1.3 to 24 months). The most common all-grade AEs regardless of cause occurring in &amp;gt;/= 50% of patients were nausea (61%), diarrhea (57%), anemia (52%) and thrombocytopenia (52%); and most common Grade 3/4 AEs were thrombocytopenia (48%), anemia (44%) and febrile neutropenia (44%). At data cut-off of August 01, 2018, 14 patients (61%) remained in the study [&lt;ulink linkID="2122967" linkType="Reference"&gt;2122967&lt;/ulink&gt;].  In June 2019, further data were presented at the 55th ASCO Annual Meeting in Chicago, IL. The most common serious AE in was febrile neutropenia (n = 9). A total of six deaths occurred during the study which was considered unrelated to treatment. The median time to achieve CR and CR + CRh was 3.7 and 2.8 months, respectively   [&lt;ulink linkID="2156048" linkType="Reference"&gt;2156048&lt;/ulink&gt;], [&lt;ulink linkID="2158776" linkType="Reference"&gt;2158776&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2018, clinical data from an open label, two-period, fixed sequence study (&lt;ulink linkID="265631" linkType="Protocol"&gt;NCT02831972&lt;/ulink&gt;) were presented at the 30th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. Subjects (n = 22) received single dose of ivosidenib (250 mg, at 0 h on day-1) in period-1; in period-2, subjects received itraconazole (multiple po doses for 18 consecutive doses; days-4 to 14) + single dose of ivosidenib (250 mg, at 0 h on day-1). Ivosidenib alone or with itraconazole were well-tolerated with similar favorable safety profiles.AUC (0 to infinity), Cmax, Tmax, t1/2 and apparent oral clearance was 115, 000 ng.h/ml, 2240 ng/ml, 4 h, 60.7 h and 2.31 l/h (ivosidenib); 302, 300 ng.h/ml, 2270 ng/ml, 4 h, 140 h and 0.863 l/h (ivosidenib + itraconazole), respectively [&lt;ulink linkID="2094780" linkType="Reference"&gt;2094780&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2015, a non-randomized, interventional, parallel assignment, open label, multicenter phase I trial (&lt;ulink linkID="248964" linkType="Protocol"&gt;NCT02632708&lt;/ulink&gt;; AG120-221-C-001) was initiated in the US in patients (expected n = 90) with newly  diagnosed AML to evaluate the safety of ivosidenib and &lt;ulink linkID="86597" linkType="Drug"&gt;enasidenib&lt;/ulink&gt; when given in combination with standard AML induction and consolidation therapy. At that time, the trial was expected to be initiated in Germany and Netherlands and was expected to complete in December 2020 [&lt;ulink linkID="1723333" linkType="Reference"&gt;1723333&lt;/ulink&gt;].  In December 2017, initial results were presented from 88 subjects at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. At the data cutoff  August 1, 2017, in ivosidenib versus enasidenib groups, in overall, de-novo and secondary AML patients complete response (CR)+CR with incomplete hematologic recovery (CRi)/CR with incomplete platelet recovery (CRp) was achieved by 23, 19, and 4 versus 31, 18 and 13, respectively; CR was achieved by 19, 15 and 4 versus 25, 16 and 9, respectively; CRi/CRp was achieved by 4, 4 and not applicable (NA) versus 6, 2 and 4, respectively; morphologic leukemic-free state was achieved by 1, NA and 1 versus 10, 4 and 6, respectively; partial response was achieved by 2, 1 and 1 only in ivosidenib groups, respectively; persistent disease (stable disease + disease progression) patients were 2, 1 and 1 versus 5, 2 and 3, respectively; not evaluable in 2, NA and 2 versus 4, 3 and 1, respectively. There were no reports of treatment-related deaths. On day 42 of induction, persistent grade 4 thrombocytopenia was a DLT reported in enasidenib- daunorubicin+ cytarabine cohort in the absence of residual leukemia [&lt;ulink linkID="1989082" linkType="Reference"&gt;1989082&lt;/ulink&gt;]. In February 2018, patient enrollment was ongoing [&lt;ulink linkID="2005359" linkType="Reference"&gt;2005359&lt;/ulink&gt;]. In December 2018, further data were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. In de novo (n = 28) and secondary AML (n = 13) patients treated with ivosidenib + chemotherapy, CR was achieved by 22 and 5 patients, respectively; CRi/CRp was achieved by 4 and 1 patient, respectively; PR was achieved by 0 and 1 patient, respectively, and persistent disease was observed in 1 and 1 patient, respectively. Morphologic leukemic-free state (MLFS) was observed in two de novo patients. In de novo (n = 45) and secondary AML (n = 32) patients treated with enasidenib + chemotherapy, CR was achieved by 28 and 14 patients, respectively; CRi/CRp was achieved by 5 and 6 patient, respectively, MLFS observed in 4 and 6 patients, and persistent disease in 6 and 3 patients, respectively. Among secondary AML patients, PR was achieved by 1 patient. A total of 33 patients proceeded to HSCT. Flow cytometry assessments in patients achieving a CR revealed that 8/9 of those with mIDH1 and 7/12 of those with mIDH2 had minimal residual disease-negative CRs [&lt;ulink linkID="2098572" linkType="Reference"&gt;2098572&lt;/ulink&gt;]. By February 2019, patient enrollment from the phase Ib trial had been completed [&lt;ulink linkID="2120020" linkType="Reference"&gt;2120020&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2015, a phase Ib combination study of ivosidenib with standard induction was planned for initiation by the end of 2015 [&lt;ulink linkID="1704055" linkType="Reference"&gt;1704055&lt;/ulink&gt;]. In December 2015, the trial was initiated in patients (n = 90) with newly diagnosed AML with an  IDH mutation [&lt;ulink linkID="1725428" linkType="Reference"&gt;1725428&lt;/ulink&gt;]. In February 2017, enrollment was ongoing [&lt;ulink linkID="1903591" linkType="Reference"&gt;1903591&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2019, preclinical data were presented at 2019 AACR Annual Meeting in Atlanta, GA. In cell-based assay, vorasidenib inhibited pan-wildtype (wt) IDH1/2 activity (IC50 of 40 nM) and ivosidenib partially inhibited wtIDH activity (IC50: 7 microM) after 48 h of incubation Vorasidenib and ivosidenib treatment did not restore wtIDH activity. Ivosidenib plasma exposure in mice at clinically matched AUC values was found insufficient to attain IC90 of wtIDH in HCT-116 (+/+) or HCT-116 (+/R132H) tumors while vorasidenib plasma exposures were within the IC90 of wtIDH activity at clinically matched AUCs in HCT-116 (+/+) but not in HCT-116 (+/R132H) tumors. Dose-dependent reduction in 2-HG levels was observed with both vorasidenib and ivosidenib in mutant tumors but not in wt tumors. In HCT-116 (+/+) tumors, both vorasidenib and ivosidenib reduced wtIDH activity[&lt;ulink linkID="2133900" linkType="Reference"&gt;2133900&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2018, in vitro data were presented at 109th AACR Annual Meeting in Chicago, IL. Ivosidenib and azacitidine alone treatments showed increased CD235a expression but was further increased with the combination of ivosidenib + azacitidine. Increase in apoptosis was observed with concurrent ivosidenib + azacitidine treatment (0.1 and 0.3 + 1 microM, respectively), suggesting potentiation [&lt;ulink linkID="2022882" linkType="Reference"&gt;2022882&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2017, preclinical data were presented at the Society for Neuro-Oncology Annual Meeting in San Francisco, CA, which showed that ivosidenib suppressed the oncometabolite D-2-hydroxyglutarate (2-HG) in an orthotopic brain tumor model. At the doses explored, treatment with ivosidenib resulted in 85 % maximal 2-HG inhibition [&lt;ulink linkID="1983704" linkType="Reference"&gt;1983704&lt;/ulink&gt;]. Further preclinical data were presented at the same conference. In pharmacokinetic analysis, AG-120 was detectable in the brain and brain-tumor tissues of the mice but at much lower exposures compared to that observed in the plasma, suggesting that AG-120 was highly potent against the mIDH1-R132H protein in vivo [&lt;ulink linkID="1987255" linkType="Reference"&gt;1987255&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, preclinical data were presented at the 20th EHA Congress in Vienna, Austria. A good correlation was observed between PK and PD parameters in the HT-1080-mutant xenograft mouse model carrying the IDH1-R132C mutation with estimated Emax and EAUC being 101.6% and 0.787 h.microg/ml, respectively [&lt;ulink linkID="1670422" linkType="Reference"&gt;1670422&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2014, preclinical data were presented at the 26th EORTC-NCI-AACR Symposium in Barcelona, Spain. Ivosidenib (1 microM) partially restored erythropoietin-induced differentiation in TF-1 IDH1-R132H mutant cells. Intracellular 2-HG levels were lowered and myeloid differentiation was induced with ivosidenib (0.5, 1 and 5 microM) treatment in primary human blast cells cultured ex vivo from patients with DH1-mutated acute myelogenous leukemia [&lt;ulink linkID="1617654" linkType="Reference"&gt;1617654&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, preclinical data were presented at the 105th AACR Meeting in San Diego, CA. In mouse xenograft model of AML (huCD45+/CD33+) cells,  AGI-14100 (150 mg/kg) plus Ara-C (1 or 10 mg/kg) demonstrated a statistically significant decrease in the leukemia cells in bone marrow. AGI-14100 and Ara-C alone and in combination significantly decreased 2HG production in bone marrow. Decrease in 2HG production correlated with the decreased leukemia burden [&lt;ulink linkID="1537662" linkType="Reference"&gt;1537662&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2014, preclinical data were reported, demonstrating the ivosidenib was a potent (IC50 = 8 nM) and reversible inhibitor of mutant IDH-1 [&lt;ulink linkID="1517655" linkType="Reference"&gt;1517655&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2013, preclinical data were presented at the 55th ASH Meeting in New Orleans, LA. In primary human IDH1R132H/Flt-3 mutant AML mouse model, AGI-14100 (150 mg/kg for 28 days) significantly reduced the tumor burden in the peripheral blood after 1 months of bid treatment; this effect was more pronounced when combined with Ara-C when compared with either of the treatment alone [&lt;ulink linkID="1503316" linkType="Reference"&gt;1503316&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2013, data from a preclinical study conducted in a leukemia cell model were published. Data demonstrated that IDH1 mutation and the 2-HG it produces had been sufficient for the transformation of growth factor dependent pre-leukemic cells into cells to show uncontrolled proliferation in the absence of growth factors. Data also demonstrated that blockage of 2-HG production by the IDH1 inhibitor resulted in reversion of these effects. The ability of the cells to rapidly proliferate in the absence of exogenous growth factors was lost after treatment with the inhibitor [&lt;ulink linkID="1383142" linkType="Reference"&gt;1383142&lt;/ulink&gt;], [&lt;ulink linkID="1383262" linkType="Reference"&gt;1383262&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2012, preclinical data were presented at the 2012 Medicinal Chemistry Gordon Conference, New London, NH. Data demonstrated that IDH-1 inhibitor have good potency in a glioblastoma cell line containing IDH-1 mutation and attained robust tumor 2-HG inhibition in the xenograft model. In September 2012, similar data were published [&lt;ulink linkID="1330796" linkType="Reference"&gt;1330796&lt;/ulink&gt;], [&lt;ulink linkID="1330962" linkType="Reference"&gt;1330962&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2018, the EMA's Pediatric Committee adopted a positive opinion agreeing a pediatric investigation plan for treatment of acute myeloid leukaemia [&lt;ulink linkID="2062871" linkType="Reference"&gt;2062871&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In October 2016,  Agios entered into a collaboration agreement with &lt;ulink linkID="13601" linkType="Company"&gt;Abbott&lt;/ulink&gt; to develop and commercialize a companion diagnostic test for ivosidenib by using  Abbott's m2000 RealTime System to identify IDH mutations in AML patients  [&lt;ulink linkID="1806533" linkType="Reference"&gt;1806533&lt;/ulink&gt;].  In February 2018, Abbott submitted a PMA application for FDA review of an IDH1 assay on the Abbott m2000 RealTime System [&lt;ulink linkID="2005726" linkType="Reference"&gt;2005726&lt;/ulink&gt;]. In July 2018, the Abbott RealTime IDH1 companion diagnostic test was approved for the selection of patients with relapsed/refractory AML for treatment with ivosidenib [&lt;ulink linkID="2056157" linkType="Reference"&gt;2056157&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-07-22T00:00:00.000Z</StatusDate><Source id="2056485" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-31T00:00:00.000Z</StatusDate><Source id="2120020" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1126254">CStone Pharmaceuticals Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-06-02T00:00:00.000Z</StatusDate><Source id="2158280" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-20T00:00:00.000Z</StatusDate><Source id="1944055" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-11T00:00:00.000Z</StatusDate><Source id="1885696" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-20T00:00:00.000Z</StatusDate><Source id="1944055" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-20T00:00:00.000Z</StatusDate><Source id="1944055" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-11T00:00:00.000Z</StatusDate><Source id="1885696" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-20T00:00:00.000Z</StatusDate><Source id="1944055" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-20T00:00:00.000Z</StatusDate><Source id="1944055" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-11T00:00:00.000Z</StatusDate><Source id="1885696" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-20T00:00:00.000Z</StatusDate><Source id="1944055" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-02-15T00:00:00.000Z</StatusDate><Source id="2137586" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-02-15T00:00:00.000Z</StatusDate><Source id="2137586" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1108">Glioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1531603" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2444">Chondrosarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1531603" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1108">Glioma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1531603" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="6833">Chronic myelomonocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-01-16T00:00:00.000Z</StatusDate><Source id="2050118" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2444">Chondrosarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1531603" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1126254">CStone Pharmaceuticals Co Ltd</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1126254">CStone Pharmaceuticals Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1126254">CStone Pharmaceuticals Co Ltd</Company><Country id="MO">Macau</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1126254">CStone Pharmaceuticals Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1126254">CStone Pharmaceuticals Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1126254">CStone Pharmaceuticals Co Ltd</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1126254">CStone Pharmaceuticals Co Ltd</Company><Country id="MO">Macau</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-15T00:00:00.000Z</StatusDate><Source id="1903591" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-15T00:00:00.000Z</StatusDate><Source id="1903591" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-15T00:00:00.000Z</StatusDate><Source id="1903591" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15331">Celgene Corp</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-08-15T00:00:00.000Z</StatusDate><Source id="1903591" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="MO">Macau</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="HK">Hong Kong</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="MO">Macau</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-12-10T00:00:00.000Z</StatusDate><Source id="1278393" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-02-21T00:00:00.000Z</StatusDate><Source id="1533007" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-12T00:00:00.000Z</StatusDate><Source id="1626070" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-18T00:00:00.000Z</StatusDate><Source id="1723333" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-30T00:00:00.000Z</StatusDate><Source id="1681756" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-30T00:00:00.000Z</StatusDate><Source id="1681756" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-18T00:00:00.000Z</StatusDate><Source id="1723333" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15331">Celgene Corp</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-18T00:00:00.000Z</StatusDate><Source id="1723333" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-11T00:00:00.000Z</StatusDate><Source id="1885696" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-03-30T00:00:00.000Z</StatusDate><Source id="1747424" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-20T00:00:00.000Z</StatusDate><Source id="1944055" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-30T00:00:00.000Z</StatusDate><Source id="1747424" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1531603" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-25T00:00:00.000Z</StatusDate><Source id="2041256" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-26T00:00:00.000Z</StatusDate><Source id="1993762" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-07-20T00:00:00.000Z</StatusDate><Source id="2056157" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1533007" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1531603" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1531603" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-18T00:00:00.000Z</StatusDate><Source id="1723333" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-12-18T00:00:00.000Z</StatusDate><Source id="1723333" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-30T00:00:00.000Z</StatusDate><Source id="1681756" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1531603" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="6833">Chronic myelomonocytic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-21T00:00:00.000Z</StatusDate><Source id="2050118" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-20T00:00:00.000Z</StatusDate><Source id="1944055" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-06-20T00:00:00.000Z</StatusDate><Source id="1944055" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1533007" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040627">Agios Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1272">Myelodysplastic syndrome</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-31T00:00:00.000Z</StatusDate><Source id="1533007" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1126254">CStone Pharmaceuticals Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1731">Acute myelogenous leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-06-26T00:00:00.000Z</StatusDate><Source id="2049098" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Ivosidenib in combination with azacitidine for the treatment of newly diagnosed AML with an IDH1 mutation in adult patients who are 75 years of age or older, or who have comorbidities that preclude use of intensive induction chemotherapy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-26T00:00:00.000Z</MileStoneDate><Source id="2135580" type="TRIALREG"></Source></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1765">Cholangiocarcinoma</Indication><AwardedIndication>Treatment of patients with previously treated, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-01-09T00:00:00.000Z</MileStoneDate><Source id="1891136" type="PR"></Source></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-05-18T00:00:00.000Z</MileStoneDate><Source id="1660979" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1108">Glioma</Indication><AwardedIndication>Treatment of glioma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-05-01T00:00:00.000Z</MileStoneDate><Source id="2032906" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1516">Biliary cancer</Indication><AwardedIndication>Treatment of biliary tract cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-03-21T00:00:00.000Z</MileStoneDate><Source id="2028500" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1516">Biliary cancer</Indication><AwardedIndication>Treatment of biliary tract cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-15T00:00:00.000Z</MileStoneDate><Source id="2012555" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1765">Cholangiocarcinoma</Indication><AwardedIndication>Treatment of cholangiocarcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-04-26T00:00:00.000Z</MileStoneDate><Source id="1923113" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-12-12T00:00:00.000Z</MileStoneDate><Source id="1887616" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukaemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-11-04T00:00:00.000Z</MileStoneDate><Source id="1874733" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukemia (AML)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-06-09T00:00:00.000Z</MileStoneDate><Source id="1669101" type="PR"></Source></Row><Row><RegulatoryDesignation id="9">Paediatric Investigation Plan</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of acute myeloid leukemia</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-07-27T00:00:00.000Z</MileStoneDate><Source id="2062871" type="PR"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1126254">CStone Pharmaceuticals Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of patients with newly diagnosed AML with an IDH1 mutation  </AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-04-24T00:00:00.000Z</MileStoneDate><Source id="2158280" type="PR"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of patients with newly diagnosed AML with an IDH1 mutation who are not eligible for standard treatment</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-02-20T00:00:00.000Z</MileStoneDate><Source id="2121506" type="PR"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment of patients with relapsed or refractory acute myeloid leukemia with an IDH1 mutation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-16T00:00:00.000Z</MileStoneDate><Source id="2005726" type="PR"></Source></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="1040627">Agios Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="1731">Acute myelogenous leukemia</Indication><AwardedIndication>Treatment for patients with relapsed or refractory acute myeloid leukemia (R/R AML) and an isocitrate dehydrogenase-1 (IDH1) mutation</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-26T00:00:00.000Z</MileStoneDate><Source id="1993762" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="GTGT-11855"><Name>IDH1 gene</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2158776" linkType="reference" linkID="2158776"&gt;2158776&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2161231" linkType="reference" linkID="2161231"&gt;2161231&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1032764">Thermo Fisher Scientific Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1040627">Agios Pharmaceuticals Inc</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>8</CountTotal></Company><Company><Company id="1056444">Foundation Medicine Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1126254">CStone Pharmaceuticals Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="13601">Abbott Laboratories</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15331">Celgene Corp</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="21864">University of Texas System</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>4</CountActive><CountInactive>0</CountInactive><CountTotal>4</CountTotal></Type><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="2">Drug - Screening/Evaluation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1ccc(c(c1)[C@@H](C(=O)NC2CC(C2)(F)F)N(c3cc(cnc3)F)C(=O)[C@@H]4CCC(=O)N4c5cc(ccn5)C#N)Cl</Smiles></StructureSmiles><Deals><Deal id="130189" title="Celgene and Agios to develop cancer metabolism therapeutics worldwide excluding the US   "></Deal><Deal id="133133" title="Agios to receive grants from the US government for the development of cancer metabolism therapeutics "></Deal><Deal id="144665" title="Foundation Medicine to identify cancer-related tumor gene alterations in patients treating with IDH-1 and IDH-2 for Agios "></Deal><Deal id="146477" title="Agios Pharmaceuticals to receive funding from the NIDA to develop AG-120 for cancer "></Deal><Deal id="162748" title="Agios and Abbott to develop and commercialize companion diagnostic tests for enasidenib and AG-120 using m2000 RealTime System in AML   "></Deal><Deal id="162757" title="Celgene and Abbott to develop and commercialize companion diagnostic tests for enasidenib and AG-120 using m2000 RealTime System in AML     "></Deal><Deal id="239204" title="TFS and Agios to develop NGS oncology CDx for ivosidenib against cholangiocarcinoma worldwide"></Deal><Deal id="247856" title="CStone to develop and commercialize Agios' ivosidenib for AML and cholangiocarcinoma in Mainland China, Hong Kong, Macau and Taiwan  "></Deal><Deal id="253891" title="MD Anderson to conduct phase I study of Agios' ivosidenib or enasidenib in combination with azacitidine against AML   "></Deal></Deals><PatentFamilies><PatentFamily id="2565033" number="WO-2013107291" title="Therapeutically active compounds and their methods of use"></PatentFamily><PatentFamily id="2995926" number="WO-2015127173" title="Therapeutically active compounds and their methods of use"></PatentFamily><PatentFamily id="2996142" number="WO-2015127172" title="Therapeutically active compounds and their methods of use"></PatentFamily><PatentFamily id="3030753" number="WO-2015138839" title="Pharmaceutical compositions of therapeutically active compounds"></PatentFamily><PatentFamily id="3423077" number="US-09474779" title="Therapeutically active compositions and their methods of use"></PatentFamily><PatentFamily id="3604898" number="WO-2017066566" title="Combination therapy for treating malignancies"></PatentFamily><PatentFamily id="3604903" number="WO-2017066571" title="Combination therapy for treating malignancies"></PatentFamily><PatentFamily id="3660845" number="WO-2017096150" title="Methods of treatment of malignancies"></PatentFamily><PatentFamily id="3774141" number="WO-2017146794" title="IDH2 inhibitors for the treatment of haematological maligancies and solid tumours"></PatentFamily><PatentFamily id="4304282" number="WO-2018231799" title="Methods of treating brain tumors using combination therapy"></PatentFamily><PatentFamily id="4515935" number="WO-2019099653" title="Therapeutically active compounds and their methods of use"></PatentFamily><PatentFamily id="4525791" number="WO-2019104318" title="Solid state forms of ivosidenib"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Xyleco Inc" id="1003962"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Agios Pharmaceuticals Inc" id="1040627"></CompanyLink><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celgene Corp" id="15331"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Stanford University" id="20679"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>